RxDoctor Payments Data

Samina Kajani

Family · Sacramento, CANPI 1548815707

Payments from drug & device makers

$426in general payments, 2019–2025

Across 14 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$138
  • Insmed, Inc.$49
  • Sanofi$38
  • Takeda Pharmaceuticals U.S.A., Inc.$34
  • Verona Pharma, Inc.$31
  • Amgen$29
  • plus $107 from 5 others

What the payments were for

  • Food & beverage$426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$426 in reported general payments places this provider in the 55th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$83,002
Medicare patients
352
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter389$284,842
Breztri AerosphereBudesonide/Glycopyr/Formoterol229$182,409
Spiriva HandihalerTiotropium Bromide88$63,486
Spiriva RespimatTiotropium Bromide71$48,619
Breo ElliptaFluticasone/Vilanterol66$35,335
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr48$29,760
Incruse ElliptaUmeclidinium Bromide67$29,680
SymbicortBudesonide/Formoterol Fumarate67$27,836
Advair HfaFluticasone Propion/Salmeterol55$20,550
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$14,050
XareltoRivaroxaban16$13,088
Tiotropium Bromide16$10,611
Combivent RespimatIpratropium/Albuterol Sulfate18$9,521
DuleraMometasone/Formoterol18$9,281
Albuterol Sulfate HfaAlbuterol Sulfate444$8,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$24$379,617570 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$138$72,191114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,634 family providers in California.

Other family in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →